Share Twitter LinkedIn Facebook Email Luis G. Paz-Ares, MD, PHD will be presenting Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial June 1st, 2019 McCormick Place Hall D2, 3pm
Lurbinectedin: Enhancing Immunotherapy Efficacy in Small Cell Lung Cancer Small Cell Lung Cancer 3 Mins Read
HARPOON THERAPEUTICS: New data on HPN328 T cell engager at ESMO 2023 Small Cell Lung Cancer 2 Mins Read
Emerging Treatment for SCLC – Leading Developments & Current Questions in Lung Cancer Small Cell Lung Cancer 1 Min Read